List of RNA Therapies Companies in Spain - 4

ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. ARTHEx has developed its proprietary technology, the ENTRY ™ platform, that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role. The first investigational product from this platform is ATX-01, an antimiR in preclinical development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis. To learn more about Arthex Biotech, please visit us at www.arthexbiotech.com

DESTINA Genomics Ltd. is a biotech company founded in Edinburgh in 2011 by Hugh Ilyine, Juan J. Diaz-Mochon and Mark Bradley. In July 2012, it was created the Spanish subsidiary DESTINA Genomica S.L. with the goal to accelerate a long-term growth plan. The company is focused on the application and validation of its patented state-of-the-art technologies. DESTINA has created a unique and reliable chemistry for highly specific detection of nucleic acids. It can be used to identify any known target nucleic acid sequence, and in particular can directly detect small RNAs, without the multiple steps required by current methods. DESTINA mission is to become a leading manufacturer and supplier of custom chemical reagents and technologies for ‘best in class' nucleic acid based biomarker assays. DESTINA's technology introduces cheaper, more accurate and much more meaningful Nucleic Acid Testing tools.

Highlight, formerly known as Bioncotech Therapeutics S.L, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Its lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors. In addition to in-house research, Highlight Therapeutics has a number of external collaborators, including Merck & Co and UCLA.

Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic therapies via interference RNA, a powerful tool for rational drug design. Most advanced product of the company are treatments for glaucoma and dry eye syndrome.